KOD News and Press, Kodiak Sciences Inc From 12/11/23

2023-12-11 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Veru, Kodiak S...

2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire PALO ALTO, Calif. , Nov. 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing ...

2023-11-17 12:41:25 ET Gainers: Altamira Therapeutics Ltd ( CYTO ) +255% . Safe and Green Development Corp ( SGD ) +89% . Fortress Biotech ( FBIO ) +50% . Mural Oncology Plc ( MURA ) +40% . Syntec Optics Holdings ( OPTX ) +35% . ...

2023-11-17 10:00:08 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Curis, Emergen...

2023-11-14 16:39:09 ET More on Kodiak Sciences Kodiak's Uncertain Path: Reallocating The Cash Reserve (Rating Downgrade) Kodiak says Phase 3 trial for lead asset met key goals Kodiak Sciences CMO resigns following failed Phase 3 studies for lead drug Seeking ...

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , Nov. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarte...

2023-11-13 08:22:15 ET Losers: Aclaris Therapeutics ( ACRS ) -85% announces top-line results from 12-Week phase 2b trial of Oral Zunsemetinib . Verve Therapeutics ( VERV ) -38% . Syntec Optics Holdings ( OPTX ) -10% . Motus GI Holdings ( MOTS ...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Kodiak Sciences Inc (KOD) is expected to report $-1.41 for Q3 2023